Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -320.09% | 4.33% | 31.09% | 66.55% | 95.09% |
| Gross Profit | 320.09% | -4.33% | -31.09% | -66.55% | -95.09% |
| SG&A Expenses | 22.63% | -13.65% | 40.56% | 72.52% | 79.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.29% | -0.11% | 32.82% | 67.77% | 91.99% |
| Operating Income | 4.29% | 0.11% | -32.82% | -67.77% | -91.99% |
| Income Before Tax | -0.84% | -6.65% | -46.10% | -67.22% | -81.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.84% | -6.65% | -46.10% | -67.22% | -81.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.84% | -6.65% | -46.10% | -67.22% | -81.40% |
| EBIT | 4.29% | 0.11% | -32.82% | -67.77% | -91.99% |
| EBITDA | -90.72% | -0.15% | -32.92% | -68.88% | 2.35% |
| EPS Basic | 7.55% | -6.02% | -45.76% | 8.09% | 96.66% |
| Normalized Basic EPS | 7.55% | -6.03% | -45.78% | 4.14% | 96.66% |
| EPS Diluted | 7.55% | -6.02% | -45.76% | 8.09% | 96.66% |
| Normalized Diluted EPS | 7.55% | -6.03% | -45.78% | 4.14% | 96.66% |
| Average Basic Shares Outstanding | 9.08% | 0.60% | 0.23% | 81.93% | 5,327.03% |
| Average Diluted Shares Outstanding | 9.08% | 0.60% | 0.23% | 81.93% | 5,327.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |